There is significant loss of activity observed during radioembolization, which can have a major dosimetric impact. The total administered activity and the number of split injections during radioembolization are the main influencing factors. Further prospective studies as well as measures of clinical outcome are warranted.

prognostic variables. Univariate and multivariate analysis showed that none of the parameters were associated with OS. Conclusion Among the parameters of FDG PET/CT, TLG 3.0 was the independent prognostic factor for DFS and maybe associated with overall survival.

No abstract

Introduction/Background The objective of this study was to analyse the utility of pretreatment 18 F-FDG-PET/CT metabolic parameters to predict non-complete cytoreduction in patients with epithelial ovarian cancer.

Result(s)* 8 OCs occurred during 1277 women screen years; 2 occult OCs at RRSO (both stage 1a), 6 screen-detected OCs (3 prevalent; stage 2a, 3aii and 3c, 3 incident; stage 1a, 3b and 4b). 4 of 6 (67%) screen-detected OCs were diagnosed at stages <3c. 7 of 8 (87.5%) screen-detected cancers were completely cytoreduced. There were no interval cancers. Modelled sensitivity, specificity, PPV and NPV for OC were 87.5% (CI, 47.3-99.7), 99.9%(99.9-100), 75%(34.9-96.8) and 99.9% (99.9-100) respectively. Economic modelling indicated that surveillance would be cost-saving within the UK National Health Service. Conclusion* OC surveillance for women declining RRSO in a 'real-word' setting is feasible and equally effective as in research trials, resulting in successful downstaging with likely clinical benefit and healthcare cost savings. Whilst RRSO remains the recommended management for BRCA-carriers, ROCA-based surveillance is a viable interim option for those who defer such surgery.